vs
Side-by-side financial comparison of Bolt Biotherapeutics, Inc. (BOLT) and EMERSON RADIO CORP (MSN). Click either name above to swap in a different company.
Bolt Biotherapeutics, Inc. is the larger business by last-quarter revenue ($2.5M vs $1.9M, roughly 1.3× EMERSON RADIO CORP). EMERSON RADIO CORP runs the higher net margin — -36.7% vs -265.2%, a 228.5% gap on every dollar of revenue. Over the past eight quarters, EMERSON RADIO CORP's revenue compounded faster (-7.3% CAGR vs -31.2%).
Bolt Biotherapeutics, Inc. is a clinical-stage biotechnology company specializing in immune-stimulating antibody conjugate (ISAC) therapies for cancer treatment. Its core pipeline targets hard-to-treat solid tumors, serving global oncology markets and advancing novel immunotherapies that trigger targeted anti-tumor immune responses to improve patient outcomes.
Emerson Radio Corporation is one of the United States' largest volume consumer electronics distributors and has a recognized trademark in continuous use since 1912. The company designs, markets, and licenses many product lines worldwide, including products sold, and sometimes licensed, under the brand name G Clef, an homage to Emerson's logo.
BOLT vs MSN — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $2.5M | $1.9M |
| Net Profit | $-6.6M | $-694.0K |
| Gross Margin | — | 10.9% |
| Operating Margin | -283.4% | -43.7% |
| Net Margin | -265.2% | -36.7% |
| Revenue YoY | — | -52.8% |
| Net Profit YoY | 58.4% | -31.7% |
| EPS (diluted) | $-9.38 | $-0.03 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $2.5M | $1.9M | ||
| Q3 25 | $2.2M | $1.2M | ||
| Q2 25 | $1.8M | $1.7M | ||
| Q1 25 | $1.2M | $1.8M | ||
| Q4 24 | $0 | $4.0M | ||
| Q3 24 | $1.1M | $2.7M | ||
| Q2 24 | $1.3M | $2.2M | ||
| Q1 24 | $5.3M | $2.2M |
| Q4 25 | $-6.6M | $-694.0K | ||
| Q3 25 | $-7.1M | $-1.0M | ||
| Q2 25 | $-8.6M | $-1.1M | ||
| Q1 25 | $-11.0M | $-2.4M | ||
| Q4 24 | $-15.9M | $-527.0K | ||
| Q3 24 | $-15.2M | $-881.0K | ||
| Q2 24 | $-21.2M | $-962.0K | ||
| Q1 24 | $-10.8M | $-883.0K |
| Q4 25 | — | 10.9% | ||
| Q3 25 | — | -0.1% | ||
| Q2 25 | — | 0.7% | ||
| Q1 25 | — | -3.0% | ||
| Q4 24 | — | 12.3% | ||
| Q3 24 | — | 9.9% | ||
| Q2 24 | — | 8.8% | ||
| Q1 24 | — | 15.9% |
| Q4 25 | -283.4% | -43.7% | ||
| Q3 25 | -355.1% | -98.4% | ||
| Q2 25 | -510.5% | -78.1% | ||
| Q1 25 | -991.4% | -137.8% | ||
| Q4 24 | — | -18.3% | ||
| Q3 24 | -1441.1% | -40.8% | ||
| Q2 24 | -1772.3% | -55.6% | ||
| Q1 24 | -324.1% | -52.2% |
| Q4 25 | -265.2% | -36.7% | ||
| Q3 25 | -329.4% | -85.8% | ||
| Q2 25 | -474.6% | -68.1% | ||
| Q1 25 | -903.4% | -127.9% | ||
| Q4 24 | — | -13.2% | ||
| Q3 24 | -1330.1% | -32.2% | ||
| Q2 24 | -1662.4% | -43.8% | ||
| Q1 24 | -205.0% | -40.1% |
| Q4 25 | $-9.38 | $-0.03 | ||
| Q3 25 | $-3.72 | $-0.05 | ||
| Q2 25 | $-4.46 | $-0.05 | ||
| Q1 25 | $-0.29 | $-0.10 | ||
| Q4 24 | $-13.73 | $-0.03 | ||
| Q3 24 | $-7.93 | $-0.04 | ||
| Q2 24 | $-11.12 | $-0.05 | ||
| Q1 24 | $-0.28 | $-0.04 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $27.5M | $13.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $26.5M | $18.6M |
| Total Assets | $56.7M | $20.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $27.5M | $13.3M | ||
| Q3 25 | $31.9M | $13.5M | ||
| Q2 25 | $34.8M | $15.5M | ||
| Q1 25 | $38.8M | $16.1M | ||
| Q4 24 | $47.3M | $16.4M | ||
| Q3 24 | $53.8M | $16.7M | ||
| Q2 24 | $73.7M | $18.9M | ||
| Q1 24 | $91.3M | $19.9M |
| Q4 25 | $26.5M | $18.6M | ||
| Q3 25 | $32.1M | $19.3M | ||
| Q2 25 | $38.8M | $20.4M | ||
| Q1 25 | $46.8M | $21.5M | ||
| Q4 24 | $57.2M | $23.9M | ||
| Q3 24 | $72.0M | $24.4M | ||
| Q2 24 | $85.9M | $25.3M | ||
| Q1 24 | $104.2M | $26.2M |
| Q4 25 | $56.7M | $20.1M | ||
| Q3 25 | $65.1M | $20.7M | ||
| Q2 25 | $75.5M | $23.3M | ||
| Q1 25 | $85.9M | $23.5M | ||
| Q4 24 | $99.6M | $26.4M | ||
| Q3 24 | $109.3M | $26.6M | ||
| Q2 24 | $124.2M | $28.5M | ||
| Q1 24 | $142.9M | $29.1M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-7.2M | $-228.0K |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-7.2M | $-228.0K | ||
| Q3 25 | $-9.7M | $-2.0M | ||
| Q2 25 | $-9.6M | $-514.0K | ||
| Q1 25 | $-13.4M | $-391.0K | ||
| Q4 24 | $-14.4M | $-293.0K | ||
| Q3 24 | $-14.0M | $-2.1M | ||
| Q2 24 | $-16.1M | $-840.0K | ||
| Q1 24 | $-16.8M | $-2.2M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $-301.0K | ||
| Q3 24 | $-14.0M | $-2.1M | ||
| Q2 24 | — | $-1.0M | ||
| Q1 24 | — | $-2.3M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | -7.5% | ||
| Q3 24 | -1227.6% | -77.8% | ||
| Q2 24 | — | -46.4% | ||
| Q1 24 | — | -102.3% |
| Q4 25 | — | 0.0% | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | — | 0.0% | ||
| Q1 25 | — | 0.0% | ||
| Q4 24 | — | 0.2% | ||
| Q3 24 | 3.6% | 0.3% | ||
| Q2 24 | 0.0% | 8.2% | ||
| Q1 24 | 0.0% | 0.5% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BOLT
Segment breakdown not available.
MSN
| Products | $1.8M | 95% |
| Other | $87.0K | 5% |
